{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:09:07Z","timestamp":1787584147170,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T00:00:00Z","timestamp":1548633600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of?Hunan Province","doi-asserted-by":"publisher","award":["No.2017JJ2398"],"award-info":[{"award-number":["No.2017JJ2398"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00228-019-02633-0","type":"journal-article","created":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T17:39:59Z","timestamp":1548697199000},"page":"655-663","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["SCN1A and SCN2A polymorphisms are associated with response to valproic acid in Chinese epilepsy patients"],"prefix":"10.1007","volume":"75","author":[{"given":"Lihong","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipeng","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8707-0487","authenticated-orcid":false,"given":"Zanling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,28]]},"reference":[{"key":"2633_CR1","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/S0140-6736(14)60456-6","volume":"385","author":"SL Mosh\u00e9","year":"2015","unstructured":"Mosh\u00e9 SL, Perucca E, Ryvlin P, Tomson T (2015) Epilepsy: new advances. Lancet 385:884\u2013898","journal-title":"Lancet"},{"key":"2633_CR2","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nrneurol.2016.135","volume":"12","author":"A Verrotti","year":"2016","unstructured":"Verrotti A, Mazzocchetti C (2016) Epilepsy: beyond seizures-the importance of comorbidities in epilepsy. Nat Rev Neurol 12:559\u2013560","journal-title":"Nat Rev Neurol"},{"key":"2633_CR3","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1124\/pr.115.012021","volume":"68","author":"MJ Brodie","year":"2016","unstructured":"Brodie MJ, Besag F, Ettinger AB, Mula M, Gobbi G, Comai S, Aldenkamp AP, Steinhoff BJ (2016) Epilepsy, antiepileptic drugs, and aggression: an evidence-based review. Pharmacol Rev 68:563\u2013602","journal-title":"Pharmacol Rev"},{"key":"2633_CR4","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","volume":"51","author":"P Kwan","year":"2010","unstructured":"Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, Mosh\u00e9 SL, Perucca E, Wiebe S, French J (2010) Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 51:1069\u20131077","journal-title":"Epilepsia"},{"key":"2633_CR5","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/jhg.2017.91","volume":"62","author":"MM Zhu","year":"2017","unstructured":"Zhu MM, Li HL, Shi LH, Chen XP, Luo J, Zhang ZL (2017) The pharmacogenomics of valproic acid. J Hum Genet 62:1009\u20131014","journal-title":"J Hum Genet"},{"key":"2633_CR6","doi-asserted-by":"crossref","unstructured":"Chateauvieux S, Morceau F, Dicato M, Diederich M (2010) Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol 2010","DOI":"10.1155\/2010\/479364"},{"key":"2633_CR7","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","volume":"369","author":"AG Marson","year":"2007","unstructured":"Marson AG, Al-Kharusi AM, Alwaidh M et al (2007) The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 369:1016\u20131026","journal-title":"Lancet"},{"key":"2633_CR8","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1124\/pr.117.014456","volume":"70","author":"J Oyrer","year":"2018","unstructured":"Oyrer J, Maljevic S, Scheffer IE, Berkovic SF, Petrou S, Reid CA (2018) Ion channels in genetic epilepsy: from genes and mechanisms to disease-targeted therapies. Pharmacol Rev 70:142\u2013173","journal-title":"Pharmacol Rev"},{"key":"2633_CR9","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1113\/jphysiol.2010.187484","volume":"588","author":"WA Catterall","year":"2010","unstructured":"Catterall WA, Kalume F, Oakley JC (2010) NaV1.1 channels and epilepsy. J Physiol 588:1849\u20131859","journal-title":"J Physiol"},{"key":"2633_CR10","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.bbrc.2017.07.109","volume":"491","author":"B Szulczyk","year":"2017","unstructured":"Szulczyk B, Nurowska E (2017) Valproic acid inhibits TTX-resistant sodium currents in prefrontal cortex pyramidal neurons. Biochem Biophys Res Commun 491:291\u2013295","journal-title":"Biochem Biophys Res Commun"},{"key":"2633_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0301-0082(98)00075-6","volume":"58","author":"W L\u00f6scher","year":"1999","unstructured":"L\u00f6scher W (1999) Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol 58:31\u201359","journal-title":"Prog Neurobiol"},{"key":"2633_CR12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0197-0186(00)00013-9","volume":"37","author":"CU Johannessen","year":"2000","unstructured":"Johannessen CU (2000) Mechanisms of action of valproate: a commentatory. Neurochem Int 37:103\u2013110","journal-title":"Neurochem Int"},{"key":"2633_CR13","doi-asserted-by":"publisher","first-page":"962","DOI":"10.2174\/156802612800229206","volume":"12","author":"V Zuliani","year":"2012","unstructured":"Zuliani V, Fantini M, Rivara M (2012) Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Curr Top Med Chem 12:962\u2013970","journal-title":"Curr Top Med Chem"},{"key":"2633_CR14","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1146\/annurev-pharmtox-011112-140232","volume":"54","author":"WA Catterall","year":"2014","unstructured":"Catterall WA (2014) Sodium channels, inherited epilepsy, and antiepileptic drugs. Annu Rev Pharmacol Toxicol 54:317\u2013338","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2633_CR15","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/nn1754","volume":"9","author":"FH Yu","year":"2006","unstructured":"Yu FH, Mantegazza M, Westenbroek RE, Robbins CA, Kalume F, Burton KA, Spain WJ, McKnight GS, Scheuer T, Catterall WA (2006) Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci 9:1142\u20131149","journal-title":"Nat Neurosci"},{"key":"2633_CR16","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.2217\/pgs.12.127","volume":"13","author":"BS Haerian","year":"2012","unstructured":"Haerian BS, Baum L, Tan HJ, Kwan P, Raymond AA, Saruwatari J, Nakagawa K, Mohamed Z (2012) SCN1AIVS5N+5 polymorphism and response to sodium valproate: a multicenter study. Pharmacogenomics 13:1477\u20131485","journal-title":"Pharmacogenomics"},{"key":"2633_CR17","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/tpj.2013.43","volume":"14","author":"TS Yip","year":"2014","unstructured":"Yip TS, O'Doherty C, Tan NC, Dibbens LM, Suppiah V (2014) SCN1A variations and response to multiple antiepileptic drugs. Pharmacogenomics J 14:385\u2013389","journal-title":"Pharmacogenomics J"},{"key":"2633_CR18","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.2217\/pgs-2016-0093","volume":"17","author":"X Li","year":"2016","unstructured":"Li X, Zhang J, Wu X, Yan H, Zhang Y, He RH, Tang YJ, He YJ, Tan D, Mao XY, Yin JY, Liu ZQ, Zhou HH, Liu J (2016) Polymorphisms of ABAT, SCN2A and ALDH5A1 may affect valproic acid responses in the treatment of epilepsy in Chinese. Pharmacogenomics 17:2007\u20132014","journal-title":"Pharmacogenomics"},{"key":"2633_CR19","doi-asserted-by":"publisher","first-page":"6722","DOI":"10.3892\/mmr.2017.7431","volume":"16","author":"SH Duan","year":"2017","unstructured":"Duan SH, Ma JL, Yang XL, Guo YF (2017) Simultaneous multigene mutation screening using SNPscan in patients from ethnic minorities with nonsyndromic hearingimpairment in Northwest China. Mol Med Rep 16:6722\u20136728","journal-title":"Mol Med Rep"},{"key":"2633_CR20","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.2217\/pgs.14.89","volume":"15","author":"CL Ma","year":"2014","unstructured":"Ma CL, Wu XY, Jiao Z, Hong Z, Wu ZY, Zhong MK (2014) Association of SCN1A, SCN2A and ABCC2 gene polymorphisms with the response to antiepileptic drugs in Chinese Han patients with epilepsy. Pharmacogenomics 15:1323\u20131336","journal-title":"Pharmacogenomics"},{"key":"2633_CR21","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/j.1755-5949.2012.00321.x","volume":"18","author":"BT Zhou","year":"2012","unstructured":"Zhou BT, Zhou QH, Yin JY, Li GL, Qu J, Xu XJ, Liu D, Zhou HH, Liu ZQ (2012) Effects of SCN1A and GABA receptor genetic polymorphisms on carbamazepine tolerability and efficacy in Chinese patients with partial seizures: 2-year longitudinal clinical follow-up. CNS Neurosci Ther 18:566\u2013572","journal-title":"CNS Neurosci Ther"},{"key":"2633_CR22","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1440-1681.2012.05680.x","volume":"39","author":"BT Zhou","year":"2012","unstructured":"Zhou BT, Zhou QH, Yin JY, Li GL, Xu XJ, Qu J, Liu D, Zhou HH, Liu ZQ (2012) Comprehensive analysis of the association of SCN1A gene polymorphisms with the retention rate of carbamazepine following monotherapy for new-onset focal seizures in the Chinese Han population. Clin Exp Pharmacol Physiol 39:379\u2013384","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2633_CR23","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1111\/j.1528-1167.2011.03097.x","volume":"52","author":"I Manna","year":"2011","unstructured":"Manna I, Gambardella A, Bianchi A, Striano P, Tozzi R, Aguglia U, Beccaria F, Benna P, Campostrini R, Canevini MP, Condino F, Durisotti C, Elia M, Giallonardo AT, Iudice A, Labate A, la Neve A, Michelucci R, Muscas GC, Paravidino R, Zaccara G, Zucca C, Zara F, Perucca E (2011) A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy. Epilepsia 52:e40\u2013e44","journal-title":"Epilepsia"},{"key":"2633_CR24","first-page":"416","volume":"70","author":"L Zhou","year":"2015","unstructured":"Zhou L, Cao Y, Long H, Long L, Xu L, Liu Z, Zhang Y, Xiao B (2015) ABCB1, ABCC2, SCN1A, SCN2A, GABRA1 gene polymorphisms and drug resistant epilepsy in the Chinese Han population. Pharmazie 70:416\u2013420","journal-title":"Pharmazie"},{"key":"2633_CR25","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.seizure.2009.12.004","volume":"19","author":"MB S\u00e1nchez","year":"2010","unstructured":"S\u00e1nchez MB, Herranz JL, Leno C, Arteaga R, Oterino A, Valdiz\u00e1n EM, Nicol\u00e1s JM, Ad\u00edn J, Armijo JA (2010) Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy. Seizure 19:93\u2013101","journal-title":"Seizure"},{"key":"2633_CR26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.eplepsyres.2013.09.011","volume":"107","author":"W Yun","year":"2013","unstructured":"Yun W, Zhang F, Hu C, Luo X, Xue P, Wang J, Ge Y, Meng H, Guo Y (2013) Effects of EPHX1, SCN1A and CYP3A4 genetic polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. Epilepsy Res 107:231\u2013237","journal-title":"Epilepsy Res"},{"key":"2633_CR27","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2217\/pgs.13.104","volume":"14","author":"BS Haerian","year":"2013","unstructured":"Haerian BS, Baum L, Kwan P, Tan HJ, Raymond AA, Mohamed Z (2013) SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis. Pharmacogenomics 14:1153\u20131166","journal-title":"Pharmacogenomics"},{"key":"2633_CR28","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2217\/pgs.11.141","volume":"13","author":"CC Hung","year":"2012","unstructured":"Hung CC, Chang WL, Ho JL, Tai JJ, Hsieh TJ, Huang HC, Hsieh YW, Liou HH (2012) Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization. Pharmacogenomics 13:159\u2013169","journal-title":"Pharmacogenomics"},{"key":"2633_CR29","doi-asserted-by":"publisher","first-page":"5507","DOI":"10.1073\/pnas.0407346102","volume":"102","author":"SK Tate","year":"2005","unstructured":"Tate SK, Depondt C, Sisodiya SM, Cavalleri GL, Schorge S, Soranzo N, Thom M, Sen A, Shorvon SD, Sander JW, Wood NW, Goldstein DB (2005) Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci U S A 102:5507\u20135512","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2633_CR30","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1097\/01.fpc.0000230114.41828.73","volume":"16","author":"SK Tate","year":"2006","unstructured":"Tate SK, Singh R, Hung CC, Tai JJ, Depondt C, Cavalleri GL, Sisodiya SM, Goldstein DB, Liou HH (2006) A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose. Pharmacogenet Genomics 16:721\u2013726","journal-title":"Pharmacogenet Genomics"},{"issue":"Suppl 1","key":"2633_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00228-013-1504-x","volume":"69","author":"E Eliasson","year":"2013","unstructured":"Eliasson E, Lindh JD, Malmstr\u00f6m RE, Beck O, Dahl ML (2013) Therapeutic drug monitoring for tomorrow. Eur J Clin Pharmacol 69(Suppl 1):25\u201332","journal-title":"Eur J Clin Pharmacol"},{"key":"2633_CR32","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.tig.2004.02.001","volume":"20","author":"RR Copley","year":"2004","unstructured":"Copley RR (2004) Evolutionary convergence of alternative splicing in ion channels. Trends Genet 20:171\u2013176","journal-title":"Trends Genet"},{"key":"2633_CR33","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1086\/516650","volume":"80","author":"EL Heinzen","year":"2007","unstructured":"Heinzen EL, Yoon W, Tate SK, Sen A, Wood NW, Sisodiya SM, Goldstein DB (2007) Nova2 interacts with a cis-acting polymorphism to influence the proportions of drug-responsive splice variants of SCN1A. Am J Hum Genet 80:876\u2013883","journal-title":"Am J Hum Genet"},{"key":"2633_CR34","doi-asserted-by":"publisher","first-page":"36700","DOI":"10.1074\/jbc.M111.250225","volume":"286","author":"EV Fletcher","year":"2011","unstructured":"Fletcher EV, Kullmann DM, Schorge S (2011) Alternative splicing modulates inactivation of type 1 voltage-gated sodium channels by toggling an amino acid in the first S3-S4 linker. J Biol Chem 286:36700\u201336708","journal-title":"J Biol Chem"},{"key":"2633_CR35","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1038\/s41598-017-01851-9","volume":"7","author":"LL Anderson","year":"2017","unstructured":"Anderson LL, Hawkins NA, Thompson CH, Kearney JA, George AL Jr (2017) Unexpected efficacy of a novel sodium channel modulator in Dravet syndrome. Sci Rep 7:1682","journal-title":"Sci Rep"},{"key":"2633_CR36","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1093\/brain\/aws151","volume":"135","author":"A Brunklaus","year":"2012","unstructured":"Brunklaus A, Ellis R, Reavey E, Forbes GH, Zuberi SM (2012) Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome. Brain 135:2329\u20132336","journal-title":"Brain"},{"key":"2633_CR37","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.pharmthera.2017.03.002","volume":"177","author":"I Younus","year":"2017","unstructured":"Younus I, Reddy DS (2017) Epigenetic interventions for epileptogenesis: a new frontier for curing epilepsy. Pharmacol Ther 177:108\u2013122","journal-title":"Pharmacol Ther"},{"key":"2633_CR38","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.biochi.2013.02.006","volume":"95","author":"R Kumari","year":"2013","unstructured":"Kumari R, Lakhan R, Kumar S, Garg RK, Misra UK, Kalita J, Mittal B (2013) SCN1AIVS5-91G>A polymorphism is associated with susceptibility to epilepsy but not with drug responsiveness. Biochimie 95:1350\u20131353","journal-title":"Biochimie"},{"key":"2633_CR39","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.gene.2013.09.071","volume":"533","author":"L Tang","year":"2014","unstructured":"Tang L, Lu X, Tao Y, Zheng J, Zhao P, Li K, Li L (2014) SCN1A rs3812718 polymorphism and susceptibility to epilepsy with febrile seizures: a meta-analysis. Gene 533:26\u201331","journal-title":"Gene"},{"key":"2633_CR40","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1097\/FPC.0b013e3283117d67","volume":"18","author":"P Kwan","year":"2008","unstructured":"Kwan P, Poon WS, Ng HK, Kang DE, Wong V, Ng PW, Lui CH, Sin NC, Wong KS, Baum L (2008) Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression. Pharmacogenet Genomics 18:989\u2013998","journal-title":"Pharmacogenet Genomics"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-019-02633-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-019-02633-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-019-02633-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T19:07:16Z","timestamp":1580152036000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-019-02633-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,28]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["2633"],"URL":"https:\/\/doi.org\/10.1007\/s00228-019-02633-0","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,28]]},"assertion":[{"value":"24 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of Xiangya Hospital Central South University Medical Ethics Committee, and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}